ts of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Drug Name(s) ICLUSIG
FDA Application No. (NDA) 203469
Active Ingredient(s) PONATINIB
Company ARIAD PHARMACEUTICALS
Original Approval or Tentative Approval Date December 14, 2012
Chemical Type 1 New molecular entity (NME)
There are no Therapeutic Equivalents
Label Information
Approval History, Letters, Reviews, and Related Documents
Products on Application (NDA) #203469
Click on a column header to re-sort the table:
Drug Name
Active Ingredients
Strength
Dosage Form/Route
Marketing
Status
RLD
TE
Code
ICLUSIG PONATINIB 15MG TABLET; ORAL Prescription No None
ICLUSIG PONATINIB 45MG TABLET; ORAL Prescription No None
